
Sign up to save your podcasts
Or


Paul Hagerman discusses a Review which highlights the latest clinical and molecular understanding of the FMR1 mutation and FXTAS.
By The Lancet NeurologyPaul Hagerman discusses a Review which highlights the latest clinical and molecular understanding of the FMR1 mutation and FXTAS.

43,673 Listeners

299 Listeners

496 Listeners

51 Listeners

112,105 Listeners

94 Listeners

514 Listeners

189 Listeners

60 Listeners

81 Listeners

0 Listeners